273 related articles for article (PubMed ID: 28194013)
1. Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state.
Rossey I; Gilman MS; Kabeche SC; Sedeyn K; Wrapp D; Kanekiyo M; Chen M; Mas V; Spitaels J; Melero JA; Graham BS; Schepens B; McLellan JS; Saelens X
Nat Commun; 2017 Feb; 8():14158. PubMed ID: 28194013
[TBL] [Abstract][Full Text] [Related]
2. Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.
Liang B; Ngwuta JO; Herbert R; Swerczek J; Dorward DW; Amaro-Carambot E; Mackow N; Kabatova B; Lingemann M; Surman S; Yang L; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Schaap-Nutt A; Collins PL; Munir S
J Virol; 2016 Nov; 90(21):10022-10038. PubMed ID: 27581977
[TBL] [Abstract][Full Text] [Related]
3. Potent Human Single-Domain Antibodies Specific for a Novel Prefusion Epitope of Respiratory Syncytial Virus F Glycoprotein.
Xun G; Song X; Hu J; Zhang H; Liu L; Zhang Z; Gong R
J Virol; 2021 Aug; 95(18):e0048521. PubMed ID: 34160257
[TBL] [Abstract][Full Text] [Related]
4. Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.
Liang B; Surman S; Amaro-Carambot E; Kabatova B; Mackow N; Lingemann M; Yang L; McLellan JS; Graham BS; Kwong PD; Schaap-Nutt A; Collins PL; Munir S
J Virol; 2015 Sep; 89(18):9499-510. PubMed ID: 26157122
[TBL] [Abstract][Full Text] [Related]
5. Clinical Potential of Prefusion RSV F-specific Antibodies.
Rossey I; McLellan JS; Saelens X; Schepens B
Trends Microbiol; 2018 Mar; 26(3):209-219. PubMed ID: 29054341
[TBL] [Abstract][Full Text] [Related]
6. Attenuated Human Parainfluenza Virus Type 1 Expressing the Respiratory Syncytial Virus (RSV) Fusion (F) Glycoprotein from an Added Gene: Effects of Prefusion Stabilization and Packaging of RSV F.
Liu X; Liang B; Ngwuta J; Liu X; Surman S; Lingemann M; Kwong PD; Graham BS; Collins PL; Munir S
J Virol; 2017 Nov; 91(22):. PubMed ID: 28835504
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the role of N-glycosylation sites in the respiratory syncytial virus fusion protein in virus replication, syncytium formation and antigenicity.
Leemans A; Boeren M; Van der Gucht W; Martinet W; Caljon G; Maes L; Cos P; Delputte P
Virus Res; 2019 Jun; 266():58-68. PubMed ID: 31004621
[TBL] [Abstract][Full Text] [Related]
8. Design and characterization of a fusion glycoprotein vaccine for Respiratory Syncytial Virus with improved stability.
Zhang L; Durr E; Galli JD; Cosmi S; Cejas PJ; Luo B; Touch S; Parmet P; Fridman A; Espeseth AS; Bett AJ
Vaccine; 2018 Dec; 36(52):8119-8130. PubMed ID: 30340881
[TBL] [Abstract][Full Text] [Related]
9. Effects of Alterations to the CX3C Motif and Secreted Form of Human Respiratory Syncytial Virus (RSV) G Protein on Immune Responses to a Parainfluenza Virus Vector Expressing the RSV G Protein.
Liang B; Kabatova B; Kabat J; Dorward DW; Liu X; Surman S; Liu X; Moseman AP; Buchholz UJ; Collins PL; Munir S
J Virol; 2019 Apr; 93(7):. PubMed ID: 30651356
[TBL] [Abstract][Full Text] [Related]
10. Transient opening of trimeric prefusion RSV F proteins.
Gilman MSA; Furmanova-Hollenstein P; Pascual G; B van 't Wout A; Langedijk JPM; McLellan JS
Nat Commun; 2019 May; 10(1):2105. PubMed ID: 31068578
[TBL] [Abstract][Full Text] [Related]
11. A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism.
Krarup A; Truan D; Furmanova-Hollenstein P; Bogaert L; Bouchier P; Bisschop IJM; Widjojoatmodjo MN; Zahn R; Schuitemaker H; McLellan JS; Langedijk JPM
Nat Commun; 2015 Sep; 6():8143. PubMed ID: 26333350
[TBL] [Abstract][Full Text] [Related]
12. Antigenicity and immunogenicity of unique prefusion-mimic F proteins presented on enveloped virus-like particles.
Kwon YM; Lee Y; Kim KH; Jung YJ; Li Z; Jeeva S; Lee S; Moore ML; Kang SM
Vaccine; 2019 Oct; 37(44):6656-6664. PubMed ID: 31542260
[TBL] [Abstract][Full Text] [Related]
13. Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein elicits antibodies targeting a membrane-proximal epitope.
McCool RS; Musayev M; Bush SM; Derrien-Colemyn A; Acreman CM; Wrapp D; Ruckwardt TJ; Graham BS; Mascola JR; McLellan JS
J Virol; 2023 Oct; 97(10):e0092923. PubMed ID: 37737588
[TBL] [Abstract][Full Text] [Related]
14. Alternative conformations of a major antigenic site on RSV F.
Jones HG; Battles MB; Lin CC; Bianchi S; Corti D; McLellan JS
PLoS Pathog; 2019 Jul; 15(7):e1007944. PubMed ID: 31306469
[TBL] [Abstract][Full Text] [Related]
15. Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein.
Cimica V; Boigard H; Bhatia B; Fallon JT; Alimova A; Gottlieb P; Galarza JM
Clin Vaccine Immunol; 2016 Jun; 23(6):451-9. PubMed ID: 27030590
[TBL] [Abstract][Full Text] [Related]
16. Immunization with Low Doses of Recombinant Postfusion or Prefusion Respiratory Syncytial Virus F Primes for Vaccine-Enhanced Disease in the Cotton Rat Model Independently of the Presence of a Th1-Biasing (GLA-SE) or Th2-Biasing (Alum) Adjuvant.
Schneider-Ohrum K; Cayatte C; Bennett AS; Rajani GM; McTamney P; Nacel K; Hostetler L; Cheng L; Ren K; O'Day T; Prince GA; McCarthy MP
J Virol; 2017 Apr; 91(8):. PubMed ID: 28148790
[TBL] [Abstract][Full Text] [Related]
17. Prefusion F, Postfusion F, G Antibodies, and Disease Severity in Infants and Young Children With Acute Respiratory Syncytial Virus Infection.
Capella C; Chaiwatpongsakorn S; Gorrell E; Risch ZA; Ye F; Mertz SE; Johnson SM; Moore-Clingenpeel M; Ramilo O; Mejias A; Peeples ME
J Infect Dis; 2017 Dec; 216(11):1398-1406. PubMed ID: 29029312
[TBL] [Abstract][Full Text] [Related]
18. Characterization of Epitope-Specific Anti-Respiratory Syncytial Virus (Anti-RSV) Antibody Responses after Natural Infection and after Vaccination with Formalin-Inactivated RSV.
Widjaja I; Wicht O; Luytjes W; Leenhouts K; Rottier PJM; van Kuppeveld FJM; Haijema BJ; de Haan CAM
J Virol; 2016 Jul; 90(13):5965-5977. PubMed ID: 27099320
[TBL] [Abstract][Full Text] [Related]
19. Stability Characterization of a Vaccine Antigen Based on the Respiratory Syncytial Virus Fusion Glycoprotein.
Flynn JA; Durr E; Swoyer R; Cejas PJ; Horton MS; Galli JD; Cosmi SA; Espeseth AS; Bett AJ; Zhang L
PLoS One; 2016; 11(10):e0164789. PubMed ID: 27764150
[TBL] [Abstract][Full Text] [Related]
20. Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses.
Mukhamedova M; Wrapp D; Shen CH; Gilman MSA; Ruckwardt TJ; Schramm CA; Ault L; Chang L; Derrien-Colemyn A; Lucas SAM; Ransier A; Darko S; Phung E; Wang L; Zhang Y; Rush SA; Madan B; Stewart-Jones GBE; Costner PJ; Holman LA; Hickman SP; Berkowitz NM; Doria-Rose NA; Morabito KM; DeKosky BJ; Gaudinski MR; Chen GL; Crank MC; Misasi J; Sullivan NJ; Douek DC; Kwong PD; Graham BS; McLellan JS; Mascola JR
Immunity; 2021 Apr; 54(4):769-780.e6. PubMed ID: 33823129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
